

Chapter 1: Introduction To Cardiovascular Disease: Global Burden, Risk Factor, And Therapeutics Gaps

Renu Sehrawat¹, Preeti Dahiya^{*2}, Sonia Narwal³, Akansha Bisht⁴

¹SGT College of Pharmacy, SGT University, Gurugram, Haryana, India

²Gurugram global college of pharmacy, Haily Mandi Rd, Farukh Nagar, Haryana, 122506, India.

³Department of Pharmacy, Panipat Institute of Engineering and Technology, Samalkha, Panipat, 132102, India.

⁴Department of Pharmacy, Jagannath University, Chaksu Bypass, Tonk Road, Jaipur, Rajasthan, 303901, India

*Corresponding Author**

Dr. Preeti Dahiya

Email: preetidahiya286@gmail.com, preetidahiya@ggcp.co.in

Abstract

The worldwide leading cause of both illness and death occurs because cardiovascular disease (CVD) creates significant difficulties for both healthcare systems and economic development. The CVD prevalence and burden exist because people develop cardiovascular disease through their controllable risk factors which include obesity and hypertension and dyslipidemia and diabetes and smoking and physical inactivity together with their unchangeable attributes of age and heredity and sex. The combination of traditional pharmacological and interventional therapies has developed through significant progress but the treatment process now faces "therapeutic gaps" because of drug resistance issues and bioavailability reduction and side effects and patient noncompliance. The chapter updates current CVD epidemiological research through a study of geographical prevalence differences and an assessment of unresolved problems that affect existing treatment methods. The chapter introduces research about new methods which combine nanotechnology with cardioprotective nutraceuticals to investigate new options in the book. This dialog will close existing gaps between contemporary cardiovascular medicine and its preventative healthcare solutions by presenting medical solutions which include both naturopathic and preventative therapies according to Steel observing the complete healing process. The presentation introduces a discussion about integrative approaches which combine nanotechnology and evidence-based nutraceuticals for their solution. The methods enhance drug delivery systems which result in better treatment outcomes while enabling cardiovascular prevention based on basic natural principles.

Keywords: Cardiovascular disease, global burden, risk factors, therapeutic gaps, nano nutraceuticals, naturopathy, cardiovascular care.

1. INTRODUCTION

Cardiovascular disease (CVD) refers to a wide range of medical conditions that impact both the heart and blood vessels which include coronary artery disease and myocardial infarction and heart failure and stroke and hypertension and peripheral vascular disease according to Preeti et al 2024. The various conditions which exist all possess similar fundamental processes that lead to cardiovascular health deterioration which results in severe medical issues and increased mortality rate according to Libby 2021. CVD which the World Health Organization WHO 2021 designates as the primary global death cause results in approximately 17.9 million annual fatalities which account for one-third of total worldwide deaths. The study shows that more than three-quarters of these deaths occur in low- and middle-income countries which demonstrates ongoing healthcare access disparities and preventive measure shortages and deficiencies in healthy lifestyle establishment. The global health landscape underwent a significant epidemiological shift during the last three decades which now shows non-communicable diseases NCDs as the primary health issue that affects people around the world according to Roth et al 2020. The shift shows strong effects in developing areas which experience fast urban growth because residents there now face higher chances of developing cardiovascular risk factors due to their consumption of unhealthy foods and decrease in exercise and tobacco use and body weight increase and extended life duration. [GBD 2019 Risk Factors Collaborators, 2020] as illustrated in figure 1. Unlike infectious diseases, which often present acute and curable conditions, CVD and other NCDs tend to follow a chronic and progressive course, thereby demanding long-term management and imposing substantial economic challenges on healthcare systems.




Figure 1.1: Overview of cardiovascular disease: Risk Factor, current therapeutic options, Therapeutics Gaps and limitations, innovative solutions, and future in cardiovascular care.

Beyond individual health outcomes, the burden of CVD extends to societal and economic dimensions. Rising healthcare expenditures for pharmacological treatments, interventional procedures, and long-term care, combined with productivity losses due to disability and premature mortality, represent a growing challenge to sustainable healthcare delivery [Bloom et al., 2018]. Consequently, addressing the global impact of CVD requires not only conventional pharmacological and surgical strategies but also preventive, holistic, and innovative approaches that can bridge existing therapeutic gaps.

2. GLOBAL BURDEN OF CARDIOVASCULAR DISEASE (CVD)

CVD currently stands as the main health problem across the world because it affects 523 million people and causes 18.6 million deaths according to 2019 statistics from the World Health Organization (WHO) and CVD deaths increased by 17 percent since 2010 according to Roth and his team who conducted their research in 2020. CVD causes approximately 33 percent of worldwide fatalities which makes it the primary cause of death that surpasses all other health problems including infectious diseases and cancers and respiratory disorders according to WHO statistics from 2021. The extensive health problems create major effects on both personal well-being and healthcare systems and worldwide economic stability. The global burden includes various factors which include both regional differences and socioeconomic status. The World Health Organization reports that over 75 percent of CVD deaths occur in low- and middle-income countries (LMICs) which face challenges because their healthcare systems lack adequate infrastructure and people cannot access preventive services and doctors take too long to diagnose cardiovascular disease (GBD 2019 Risk Factors Collaborators 2020). People in these areas have developed sedentary lifestyles and started using tobacco and eating unhealthy food and encountering environmental pollution because of the fast urbanization and economic changes that these regions have experienced. The healthcare system limitations create barriers which prevent patients from receiving necessary diagnostic tests and treatment procedures and continuous care which leads to a higher death rate in developing countries compared to developed countries according to the 2020 research of Yusuf and his team.

The demographic impact of cardiovascular disease (CVD) extends beyond older age groups. The evidence shows that obesity and diabetes and smoking have caused an alarming increase in early cardiovascular events among younger adults according to Bentham and his colleagues who conducted their research in 2020. The situation creates two problems because it requires more long-term care while workers lose productivity during their most productive years which increases the economic and social costs of CVD. The worldwide economic effects of cardiovascular disease (CVD) create a substantial financial burden on the world economy. Non-communicable diseases with cardiovascular disease (CVD) as their most common form are expected to create over \$47 trillion in economic losses for the global economy through their healthcare costs and productivity reduction and disability-adjusted life years (DALYs) by the year 2030 according to Bloom and his colleagues who conducted their study in 2018. The situation creates an overwhelming demand on national health systems which affects countries that lack proper funding and health system infrastructure. The increasing worldwide prevalence of cardiovascular disease (CVD) creates an urgent requirement for complete prevention and early diagnosis and effective treatment and sustainable care system development through integrated health programs. The current rise in medical difficulties requires new treatment methods because traditional cardiovascular treatments do not address existing medical issues which create new possibilities for affordable integrated solutions through nutritional supplements and nanotechnology-based interventions.

Risk Factors of Cardiovascular Disease (CVD)

The onset and progression of CVD are shaped by a complex interplay of modifiable factors, such as lifestyle and metabolic habits, and non-modifiable factors, including age, genetics, and family history [Preeti et al., 2023, 2024]. Understanding these determinants is critical for designing effective preventive and therapeutic strategies.

1. Modifiable Risk Factors

These are lifestyle or environment-related factors that can be controlled or altered through interventions:

- Hypertension High blood pressure acts as the primary risk factor which people can control to develop cardiovascular disease since it leads to approximately 50 percent of all ischemic heart disease and stroke cases worldwide according to Mills et al 2020. Continuous blood pressure increases lead to blood vessel destruction and left ventricular hypertrophy development which results in atherosclerosis progression that raises cardiovascular danger.

- The American Diabetes Association 2020 states that people with type 2 diabetes face two to four times the CVD risk which non-diabetic people experience. Endothelial function becomes impaired by chronic hyperglycemia and insulin resistance together with advanced glycation end-products which trigger vascular inflammation and speed up atherosclerotic development.
- Abnormal lipid profiles which show high low-density lipoprotein cholesterol LDL-C levels and low high-density lipoprotein cholesterol HDL-C levels and high triglyceride levels function as the main factors which start and advance atherosclerotic plaque development according to Ference et al 2019. The disruptions to lipid balance in the body create conditions which cause blood vessels to lose their normal function and increase the chances of coronary incidents.
- Obesity together with metabolic syndrome occurs when people gain excessive body weight especially in their central and abdominal area which leads to a higher chance of developing hypertension and insulin resistance and dyslipidemia. The combination of these metabolic disorders results in an increased risk of cardiovascular problems according to Bentham et al 2020. The current global issue has become more serious because of people who adopt sedentary lifestyles and consume high-calorie food.
- Unhealthy Diet The most essential factors which determine cardiovascular health include dietary habits according to research. High salt intake together with refined sugar and trans fat consumption leads to increased hypertension and obesity and dyslipidemia development. Regular intake of fruits and vegetables and whole grains and lean proteins and omega-3 fatty acids leads to reduced cardiovascular risks and enhanced vascular performance according to research done by Mozaffarian in 2016.
- Physical Inactivity Sedentary Lifestyle The connection between sedentary behavior and obesity and hypertension links to poor lipid profile results. The practice of physical activity decreases cardiovascular disease occurrence because it enhances endothelial function and lipid metabolism and insulin sensitivity according to research conducted by Lear and his colleagues in 2017.
- Tobacco Smoking and Alcohol Consumption Smoking tobacco causes cardiovascular disease through oxidative stress and inflammation and endothelial dysfunction. Excessive alcohol consumption raises both hypertension and cardiomyopathy development risk according to research conducted by Yusuf and his colleagues in 2020.
- Psychosocial Stress and Poor Sleep Chronic stress and depression and sleep deprivation act as risk factors through their effects on hormonal systems and their promotion of inflammatory processes and dysfunctional coping mechanisms according to research conducted by Rosengren and his colleagues in 2019.

2. Non-Modifiable Risk Factors

These cannot be altered but play a significant role in determining susceptibility to CVD:

1. **Age:** The development of cardiovascular disease remains most closely linked to advancing age as its primary risk factor. The human body experiences loss of arterial elasticity during aging which leads to increased vascular stiffness and builds up metabolic and environmental risk factors that result in cardiovascular damage. The CVD risk increase occurs because the body experiences age-related changes in both its physiological functions and cellular structures (Virani et al., 2021).
2. **Sex/Gender:** The patterns of cardiovascular risk assessment show different results between men and women because of their distinct gender profiles. Men generally face a higher likelihood of developing premature CVD compared to women of the same age. However, women experience a significant increase in their cardiovascular risk after menopause because their estrogen levels decline which leads to the disappearance of their hormonal defense system (Peters et al. 2019).
3. **Genetics and Family History:** A positive family history of premature cardiovascular events is a well-established non-modifiable risk factor. Genetic predispositions determine how the body handles lipid metabolism vascular control and inflammatory processes which results in increased severe cardiovascular disease risk for younger individuals (Khera et al., 2016).

4. **Ethnicity:** Cardiovascular risk shows different patterns according to a person's ethnic background. The South Asian population shows high vulnerability because they develop cardiovascular disease and diabetes at earlier ages with more severe symptoms than other populations. The disparity between these two groups shows how genetic factors and dietary habits and cultural traditions interact to determine disease development (Joshi et al., 2007).

The relationship between modifiable risk factors and non-modifiable risk factors presents a challenging path which researchers must follow to understand how CVD develops. The global burden of CVD can be reduced through lifestyle changes and preventive medical care and public health initiatives which focus on dietary habits and smoking cessation and exercise routines and metabolic health management. Bridging therapeutic gaps and achieving better cardiovascular outcomes require organizations to implement comprehensive risk factor management approaches according to research results that demonstrate this need

Table 1.1: Risk Factors of Cardiovascular Disease (CVD)

Category	Risk Factor	Description / Mechanism	Key References
Modifiable	Hypertension	Persistent elevation of blood pressure damages vascular endothelium, promotes left ventricular hypertrophy, and accelerates atherosclerosis.	Mills et al., 2020
	Diabetes Mellitus	Hyperglycemia and insulin resistance cause endothelial dysfunction, oxidative stress, and increased risk of coronary artery disease.	American Diabetes Association, 2020
	Dyslipidemia	Elevated LDL-C and triglycerides with reduced HDL-C promote plaque formation and vascular obstruction.	Ference et al., 2019
	Obesity & Metabolic Syndrome	Central obesity increases risk of hypertension, insulin resistance, and lipid abnormalities, amplifying CVD risk.	Bentham et al., 2020
	Unhealthy Diet	Diets rich in trans fats, sugars, and salt increase CVD risk; diets with fruits, vegetables, omega-3 reduce risk.	Mozaffarian, 2016
	Physical Inactivity (Sedentary Lifestyle)	Lack of exercise contributes to obesity, hypertension, and poor lipid profile; regular activity reduces CVD risk.	Lear et al., 2017
	Tobacco Smoking & Excessive Alcohol	Smoking increases oxidative stress and inflammation; heavy alcohol use leads to hypertension and cardiomyopathy.	Yusuf et al., 2020
	Psychosocial Stress & Sleep Disorders	Chronic stress and inadequate sleep increase hormonal imbalance, inflammation, and unhealthy behaviors.	Rosengren et al., 2019
Non-Modifiable	Age	Advancing age increases arterial stiffness, endothelial dysfunction, and cumulative exposure to risk factors.	Virani et al., 2021
	Sex/Gender	Men have higher early CVD risk; postmenopausal women's risk rises due to hormonal decline.	Peters et al., 2019
	Genetics & Family History	Genetic predispositions and family history increase likelihood of early-onset CVD.	Khera et al., 2016
	Ethnicity	Certain ethnic groups (e.g., South Asians) show higher predisposition to diabetes and CVD at younger ages.	Joshi et al., 2007

Identification of Therapeutic Gaps and Challenges in Cardiovascular Disease Management

Despite significant advancements in cardiovascular disease (CVD) treatment, several therapeutic challenges persist, impacting patient outcomes globally. These challenges encompass drug resistance, limited bioavailability of medications, adverse effects of long-term pharmacotherapy, poor patient adherence, and issues related to accessibility and affordability, particularly in under-resourced regions.

3. THERAPEUTIC OPTIONS AND GAPS IN CARDIOVASCULAR DISEASE (CVD)

Management of cardiovascular disease encompasses multiple therapeutic domains, each with distinct options and associated limitations. Lifestyle modification includes following heart-healthy dietary patterns, such as the DASH or Mediterranean diet, engaging in regular physical activity, quitting smoking, and

effectively managing stress, which form the foundation of preventing and managing CVD as discussed in Table 2 shows that effective intervention results require better compliance which remains elusive because people face socioeconomic and cultural and behavioral obstacles while they whom they serve encounter difficulties with program maintenance in low-income and middle-income countries (LMICs) (Mozaffarian 2016; Lear et al. 2017). The pharmacological therapy which contains antihypertensives such as ACE inhibitors and beta-blockers and statins and antiplatelets and anticoagulants and glucose-lowering agents delivers significant clinical benefits but faces multiple obstacles because its side effects and high costs and limited availability in poor areas and low prescription rates for primary prevention methods (Yusuf et al 2020; Virani et al 2021). The medical field uses interventional and surgical procedures which include percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG) and stenting and valve replacement and cardiac implantable devices to provide life-saving medical procedures which come with expensive treatment costs and invasive medical procedures and limited access for low and middle-income countries and their primary use during advanced disease stages instead of preventive treatment (Fihn et al 2014). The people need to know about preventive strategies which include community screening programs and awareness campaigns and early detection methods for hypertension and diabetes (Roth et al. 2020). The healthcare system needs more people to understand about primary prevention methods because these essential preventive strategies remain unused (Roth et al. 2020). Structured cardiac rehabilitation and physiotherapy with lifestyle counseling create better rehabilitation outcomes for patients yet many regions especially rural and low-income areas without proper programs do not implement these services (Anderson et al. 2016). Bioactive compounds present in nutraceuticals and integrative medicine which include omega-3 fatty acids and plant sterols and antioxidants and polyphenols offer cardiovascular protection yet their clinical application remains limited because standardized formulations do not exist and large-scale clinical studies are insufficient and their bioavailability varies (Banach et al. 2021). The field of nanotechnology develops new therapeutic methods which use nano-delivery systems to deliver statins and antioxidants and nutraceuticals through targeted drug delivery. The methods exist in preclinical and early clinical development but they encounter regulatory challenges while their long-term safety and cost-effectiveness and clinical utility await complete assessment (Khan et al. 2020).

Table 1.2: Therapeutic Options and Gaps in Cardiovascular Disease (CVD)

Therapeutic Domain	Current Options	Therapeutic Gaps / Limitations	Key References
Lifestyle Modification	Healthy diet (DASH, Mediterranean diet), regular exercise, smoking cessation, stress management	Poor adherence due to socioeconomic, cultural, and behavioral barriers; lack of long-term sustainability in LMICs	Mozaffarian, 2016; Lear et al., 2017
Pharmacological Therapy	Antihypertensives (ACE inhibitors, beta-blockers), statins, antiplatelets, anticoagulants, glucose-lowering agents	Side effects, cost barriers, limited access in resource-poor settings, under-prescription in primary prevention	Yusuf et al., 2020; Virani et al., 2021
Interventional / Surgical	PCI, CABG, stenting, valve replacement, cardiac implantable devices	High cost, invasive nature, limited availability in LMICs, late-stage application rather than prevention	Fihn et al., 2014
Preventive Strategies	Screening programs, community awareness, early detection of hypertension/diabetes	Limited awareness, inadequate healthcare infrastructure, underutilization of primary prevention services	Roth et al., 2020
Rehabilitation & Secondary Prevention	Cardiac rehabilitation, physiotherapy, lifestyle counseling	Poor uptake, lack of structured rehabilitation programs in many regions, especially rural and low-income areas	Anderson et al., 2016
Nutraceuticals & Integrative Medicine	Omega-3 fatty acids, plant sterols, antioxidants, polyphenols	Lack of standardized formulations, insufficient large-scale clinical trials, variable bioavailability	Banach et al., 2021
Nanotechnology-Based Therapeutics (Emerging)	Nano-delivery systems for statins, antioxidants, nutraceuticals; targeted drug delivery	Still in preclinical/early clinical stages, regulatory challenges, long-term safety and cost-effectiveness unproven	Khan et al., 2020

4. CURRENT THERAPEUTIC OPTIONS IN CARDIOVASCULAR DISEASE (CVD)

The management of CVD relies on a multifaceted approach combining pharmacological, surgical, and lifestyle-based interventions.

Surgical and Interventional Therapies

Interventional cardiology together with surgical operations serves as the primary treatment method which doctors use to address critical medical emergencies in the medical field. Heart disease treatment requires interventional methods and surgical procedures as essential treatment approaches.0 The medical procedure called percutaneous coronary intervention (PCI) which combines angioplasty with stent placement enables doctors to treat patients who have obstructive coronary artery disease by restoring their blood circulation to deliver immediate relief from symptoms while decreasing their chances of experiencing urgent medical situations (Neumann et al., 2019). The medical procedures of valve replacement and cardiac implantable devices which include implantable cardioverter defibrillators (ICDs) and cardiac resynchronization therapy (CRT) devices function to repair heart structural damage and electrical faults which result in decreased patient mortality and illness rates among specific groups of patients (Otto et al., 2021).

Lifestyle Modification Strategies

CVD cardiovascular disease prevention uses lifestyle modifications as its primary method while its secondary prevention methods also depend on this approach. The adoption of heart-healthy dietary patterns through DASH and Mediterranean diets leads to blood pressure reduction and lipid profile improvement which decreases cardiovascular events according to Estruch et al. 2018. Regular physical activity practice helps people develop their cardiorespiratory fitness abilities which supports weight management efforts while reducing their risk for future cardiovascular events according to Lear et al. 2017. The World Health Organization WHO 2021 recommends smoking cessation because tobacco use serves as an independent risk factor that strongly increases the chances of myocardial infarction and stroke. People who have cardiovascular disease can control their blood pressure through stress management strategies that include mindfulness practices yoga and cognitive-behavioral therapy according to Steptoe and Kivimäki 2013.

Table 1.3 shows that modern cardiovascular treatment programs depend on these medical treatments. The need for innovative treatment solutions exists because existing therapies face challenges, which include limited patient compliance and high medical expenses and adverse treatment effects and discrepancies in treatment availability.

Table 1.3: Summary of Current Therapeutic Options in Cardiovascular Disease (CVD)

Therapeutic Domain	Examples	Benefits	Limitations	Key References
Pharmacological Therapy	- Antihypertensives (ACE inhibitors, beta-blockers, calcium channel blockers) - Lipid-lowering agents (statins, fibrates) - Antiplatelets/anticoagulants - Antidiabetic/metabolic regulators (SGLT2 inhibitors, GLP-1 agonists)	- Effective in lowering BP, cholesterol, and glucose - Strong evidence from RCTs - Reduces risk of stroke, MI, and heart failure	- Side effects (e.g., statin intolerance, bleeding risk) - Poor adherence to long-term therapy - High cost in LMICs - Limited patient education	Whelton et al., 2018; Ference et al., 2019; Zinman et al., 2015
Surgical & Interventional Therapies	- PCI (angioplasty, stenting) - CABG - Valve replacement - Cardiac devices (ICD, CRT)	- Rapid symptom relief (angina, ischemia) - Improves survival in advanced disease - Restores cardiac structure/function	- Expensive and invasive - Requires specialized facilities - Higher perioperative risk - Limited access in LMICs	Neumann et al., 2019; Head et al., 2018; Otto et al., 2021
Lifestyle Modification	- DASH & Mediterranean diet - Exercise programs - Smoking cessation - Stress management	- Cost-effective & preventive - Improves overall	- Requires strong patient adherence - Cultural &	Estruch et al., 2018; Lear et al., 2017;

		health beyond CVD (diabetes, obesity) - Reduces recurrence of events - Promotes long-term wellness	socioeconomic barriers - Benefits take time to manifest - Poor long-term sustainability	Steptoe & Kivimäki, 2013; WHO, 2021
--	--	--	---	-------------------------------------

5. EMERGING NEED FOR INNOVATIVE STRATEGIES IN CARDIOVASCULAR CARE

The current medical methods which include pharmacological treatments and interventional cardiology procedures have failed to provide effective solutions for treating cardiovascular disease (CVD) because they struggle to maintain patient treatment over extended periods and they produce dangerous side effects and they cannot be used in areas with limited healthcare resources. The existing limitations established a compelling need for new solutions which combine current biomedical methods with proven naturopathic treatment methods, as demonstrated in table 4. Medical professionals have started to recognize nanotechnology as an effective solution for developing new cardiovascular treatment methods. The use of nanoformulations enables improved absorption of cardioprotective substances at higher levels by achieving better delivery to heart tissues through controlled-release systems which also decrease systemic toxicity according to [Gavasheli et al. 2020]. The precision-driven delivery models enable nutraceuticals and conventional medications to achieve their required therapeutic levels at the action site, which results in fewer needed doses and reduced side effects.

Nutraceuticals show strong cardioprotective effects through their ability to control oxidative stress and inflammation and endothelial function and lipids metabolism according to research which tested omega-3 fatty acids and flavonoids and polyphenols and coenzyme Q10 and resveratrol [Sahebkar & Serban, 2015; Cicero et al., 2020]. The compounds show potential to reduce cardiovascular risk when they become part of preventive care methods which use nano-encapsulated forms that improve absorption and stability. The combination of naturopathy and scientific progress provides an all-encompassing method for treating heart conditions. The combination of nano-nutraceuticals and plant-based diets and stress reduction methods and herbal treatments and yoga and exercise creates a system which helps people manage their diseases while preventing future health issues. The integrative framework supports global health priorities which focus on preventive healthcare and the continuing treatment of non-communicable diseases.

Table 1.4: Innovative Strategies in Cardiovascular Disease Management

Strategy	Mechanism/Focus	Advantages	References
Nanotechnology-Based Delivery	Nano-encapsulation, controlled release, targeted cardiac delivery	- Improves solubility & bioavailability - Reduces systemic toxicity - Site-specific action	Gavasheli et al., 2020; Singh et al., 2021
Nutraceuticals	Omega-3, polyphenols, flavonoids, CoQ10, resveratrol	- Reduces oxidative stress & inflammation - Modulates lipid metabolism - Preventive cardioprotective role	Sahebkar & Serban, 2015; Cicero et al., 2020
Integrative Naturopathic Approaches	Lifestyle (diet, exercise, yoga, herbal therapies) + nano-nutraceuticals	- Promotes holistic care - Preventive + therapeutic benefits - Cost-effective in long term	WHO, 2021; Sarris, 2019

6. EMERGING NEED FOR INNOVATIVE STRATEGIES IN CARDIOVASCULAR CARE

The existing pharmacological and interventional cardiology developments have not succeeded in providing complete solutions for cardiovascular disease (CVD) treatment because patients show difficulties with treatment sustainability and experience side effects while hospitals face challenges in providing care to people living in low-resource environments. The system requires new treatment methods that combine contemporary biomedical technology with proven evidence-based natural medicine methods shown in figure 2. CVD remains the leading global cause of mortality which results in 18 million deaths annually while it creates major social and medical expenses that impact every nation around the world [World Health Organization, 2021]. The traditional methods of treating diseases through medicine and surgery have extended patient life spans yet these methods fail to stop the increasing rate of CVD which affects low and middle-income countries (LMICs). The existing treatment methods face three main problems which include expensive treatment options and challenges with patients maintaining their treatment plans and the development of drug side effects which create a need for new treatment methods that focus on individual patient needs [Whelton et al., 2018; Neumann et al., 2019]. The situation demands treatment methods which combine advanced medical technology with natural health methods based on nutraceutical and naturopathic solutions.




Figure 1.2: Emerging need Holistic cardiovascular care

1. Nanotechnology-Based Solutions in Cardiovascular Medicine

Nanotechnology has developed into a revolutionary technology that improves cardiovascular treatment methods by solving the main problems which exist in traditional drug and nutraceutical delivery systems. The nontherapeutic performance of cardioprotective agents results from their three major defects, which include poor solubility, low stability and inadequate bioavailability [Singh, Sharma, & Singh, 2021]. Liposomes and polymeric nanoparticles and dendrimers and solid lipid nanoparticles which make up nano-encapsulation technologies, provide exact and targeted therapeutic agent delivery to cardiac tissues. The delivery systems show improved drug stability and bioavailability, while their controlled-release systems maintain clinical drug levels during extended durations which decreases the requirement for multiple drug administrations. The particular cardiovascular targets established by nanocarriers decrease total body exposure, which results in diminished harmful reactions that typically arise from high-dose or broad-spectrum drug treatments [Gavasheli et al., 2020]. The nanotechnology system enables the simultaneous delivery of multiple agents which includes the combination of standard drugs with cardioprotective dietary supplements, which creates synergistic effects to manage all cardiovascular risk elements. The use of nanotechnology in cardiovascular treatment represents a beneficial method which helps to close existing therapeutic voids by improving treatment results and patient safety and medication compliance.

2. Nutraceuticals in Cardiovascular Care

Nutraceuticals are dietary elements which contain biologically active substances that deliver health advantages through medical treatment and disease prevention which exceed basic nutritional value. The nutraceuticals omega-3 fatty acids and polyphenols and flavonoids and coenzyme Q10 and resveratrol demonstrate significant protective effects on heart health according to research results (Sahebkar & Serban 2015; Cicero et al. 2020). The compounds create positive health effects by activating different molecular mechanisms which include decreasing oxidative damage and blocking blood vessel inflammation and controlling fat metabolism and improving blood vessel function. Clinical research shows that people who consume these bioactive substances on a regular basis will experience decreased chances of developing atherosclerosis and hypertension and dyslipidemia. The therapeutic applications of these peptides face significant challenges because their water solubility remains weak and their metabolic rate is high and their gastrointestinal absorption remains low which limits their clinical use and therapeutic effectiveness. The systems which use nanotechnology for delivery purposes achieve better results through their ability to improve both stability and solubility and bioavailability via nano-encapsulation and nanoemulsion methods. The formulations provide continuous release of nutrients to specific body regions which helps nutraceuticals to enter the cardiovascular system while delivering their full preventive and treatment effects.

3. Integration of Naturopathy and Modern Science

The combination of naturopathy and modern medical treatments creates an all-encompassing method which prevents heart disease according to the information presented in table 5. Naturopathic treatments require patients to change their way of living through plant-based diets and stress management methods and yoga and physical exercise and herbal medicine in order to achieve cardiovascular wellness according to Sarris 2019. The modern scientific method which uses nano-encapsulated nutraceuticals together with this integrative methodology enables researchers to study both biological factors and behavioral patterns that contribute to cardiovascular disease development. The combination of nano-CoQ10 and nano-resveratrol with a heart-healthy diet produces better endothelial function and mitochondrial energy output, while stress reduction methods and physical exercise decrease neuroendocrine response and body inflammation. The combination of natural treatment methods with new drug delivery systems creates a system which protects patients from illness, improves their treatment compliance and decreases total future medical expenses. The worldwide public health needs which call for sustainable patient-focused healthcare systems that both treat and prevent heart disease suffer from implementation issues due to these integrated approaches.

Table 1.5: Innovative Strategies for Cardiovascular Disease Management

Strategy	Mechanism/Focus	Advantages	Limitations	References
Nanotechnology-Based Delivery	Nano-encapsulation, liposomes, polymeric carriers, controlled release	- Enhances solubility & bioavailability - Provides targeted delivery to cardiac tissue - Reduces systemic toxicity - Allows combination therapy	- High production costs - Limited large-scale clinical trials	Gavasheli et al., 2020; Singh et al., 2021
Nutraceuticals	Omega-3 fatty acids, polyphenols, flavonoids, CoQ10, resveratrol	- Reduces oxidative stress & inflammation - Improves lipid metabolism & endothelial function - Preventive cardioprotective role	- Poor stability & absorption in conventional form - Variability in evidence quality	Sahebkar & Serban, 2015; Cicero et al., 2020
Integrative Naturopathic Approaches	Lifestyle modifications (diet, yoga, stress reduction, herbal therapies) + nano-nutraceuticals	- Promotes holistic care - Preventive + therapeutic benefits - Cost-effective and culturally adaptable	- Requires strong patient adherence - Limited institutional integration	Sarris, 2019; WHO, 2021

CONCLUSION

The ongoing increase of CVDs represents one of the primary global causes that lead to both sickness and death. The worldwide health crisis persists due to multiple factors which include changes in lifestyle and the natural aging process and inherent genetic factors and environmental hazards. The development of pharmaceutical treatments together with surgical techniques has resulted in better patient outcomes; however, there exists a treatment gap which affects both long-term disease control and prevention of recurring heart disease and management of medication side effects. The cardiovascular care system requires these treatment requirements to achieve both long-term success and effective operations. The field of medicine now requires integrative methods which combine established medical practices with complementary approaches. The combination of nano-formulated cardio nutraceuticals with naturopathic treatments represents an emerging field in this particular area. Nano-cardio nutraceuticals represent a cutting-edge method which improves the delivery system of omega-3 fatty acids and polyphenols and flavonoids and coenzyme Q10 (CoQ10) through better absorption. Naturopathic methods use dietary changes and herbal medicine and lifestyle practices and complete body health approaches to help patients achieve physiological balance and decrease oxidative damage and strengthen their cardiovascular health. The combination of nanotechnology and nutraceutical science and naturopathy creates a new multidimensional medical approach which studies preventive methods and personalized treatment. The integrated framework connects current scientific progress with traditional organic medicine to provide better cardiovascular treatment methods which will decrease long-term health costs while enhancing worldwide patient life standards. The conclusion establishes the base for upcoming book chapters which will explain scientific principles and formulation methods and clinical uses and mechanistic details of nano cardio nutraceuticals. The text guides readers from understanding the global CVD burden through the discovery of technology-based and nature-based treatment methods which create advanced cardiovascular medical solutions.

Acknowledgement: The authors would like to thank the Editors and Deep Science Publishers for providing this valuable opportunity.

Author Contribution: All authors contributed equally to the conception, design, writing, and finalization of this work. Each author was actively involved in literature review, data interpretation, manuscript preparation, and critical revision. **Akansha Bisht**, specifically contributed to drafting, grammatical modification, and overall quality improvement of the manuscript. All authors have read and approved the final version of the manuscript and agree to be accountable for all aspects of the work.

Funding: No funding.

Conflict of Interest: There is no conflict of interest.

REFERENCES

1. American Diabetes Association. (2020). 10. Cardiovascular disease and risk management: standards of medical care in diabetes—2020. *Diabetes care*, 43(Supplement_1), S111-S134.
2. Anderson, L., Oldridge, N., Thompson, D. R., Zwisler, A. D., Rees, K., Martin, N., & Taylor, R. S. (2016). Exercise-based cardiac rehabilitation for coronary heart disease. *Cochrane Database of Systematic Reviews*, 2016(1), CD001800. <https://doi.org/10.1002/14651858.CD001800.pub3>
3. Anderson, L., Oldridge, N., Thompson, D. R., Zwisler, A. D., Rees, K., Martin, N., & Taylor, R. S. (2016). Exercise-based cardiac rehabilitation for coronary heart disease. *Journal of the American College of Cardiology*, 67(1), 1–12. <https://doi.org/10.1016/j.jacc.2015.10.044>
4. Amar K, Sahoo S, Mishra R, Dutta P, Ghosh B, Pal R. Lipidic nanocarriers (liposomes): A potential targeting strategy for cosmeceutical and therapeutic applications—an in-depth review. *Curr Nanomed*. 2026;16:e24681873411316. doi:10.2174/0124681873411316251118051648.
5. Banach, M., Penson, P. E., Al-Rasadi, K., Toth, P. P., Farnier, M., Giglio, R. V., ... & Rysz, J. (2021). Nutraceuticals in cardiovascular disease prevention. *Current Opinion in Lipidology*, 32(6), 361–372. <https://doi.org/10.1097/MOL.0000000000000776>
6. Bentham, J., Di Cesare, M., Bilano, V., Bixby, H., Zhou, B., Stevens, G. A., ... & NCD Risk Factor Collaboration (NCD-RisC). (2020). Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: A pooled analysis of 2416 population-based measurement studies in 128.9 million children, adolescents, and adults. *The Lancet*, 390(10113), 2627–2642. [https://doi.org/10.1016/S0140-6736\(17\)32129-3](https://doi.org/10.1016/S0140-6736(17)32129-3)

7. Pal R, Pandey P, Chawra HS, Khan Z. Nano drug delivery carriers (Nanocarriers): A promising targeted strategy in tuberculosis and pain treatment. *Pharmaceutical Nanotechnology*. 2025 Mar 7.
8. Cicero, A. F., Colletti, A., Bajraktari, G., Descamps, O., Djuric, D. M., Ezhov, M., ... & Mikhailidis, D. P. (2020). Lipid-lowering nutraceuticals in clinical practice: Position paper from an International Lipid Expert Panel. *Pharmacological Research*, 153, 104644.
9. Estruch, R., Ros, E., Salas-Salvadó, J., Covas, M. I., Corella, D., Arós, F., ... & Martínez-González, M. A. (2018). Primary prevention of cardiovascular disease with a Mediterranean diet supplemented with extra-virgin olive oil or nuts. *New England Journal of Medicine*, 378(25), e34. <https://doi.org/10.1056/NEJMoa1800389>
10. Teli S, Shah TM. Design solid lipid nanoparticle solid lipid nanoparticle (SLNs) of dapagliflozin for enhanced oral bioavailability and controlled release in type 2 diabetes. *African Journal of Biological Sciences*. 2022;4(1):287-306.
11. Ference, B. A., Graham, I., Tokgozoglu, L., & Catapano, A. L. (2019). Impact of lipids on cardiovascular health. *Journal of the American College of Cardiology*, 72(10), 1141–1156. <https://doi.org/10.1016/j.jacc.2018.06.046>
12. Fihn, S. D., Blankenship, J. C., Alexander, K. P., Bittl, J. A., Byrne, J. G., Fletcher, B. J., ... & Smith, S. C. (2014). 2014 ACC/AHA/AATS/PCNA/SCAI/STS focused update on the guideline for the diagnosis and management of patients with stable ischemic heart disease. *Circulation*, 130(19), 1749–1767. <https://doi.org/10.1161/CIR.0000000000000095>
13. Fihn, S. D., Gardin, J. M., Abrams, J., Berra, K., Blankenship, J. C., Dallas, A. P., ... & Smith, S. C. (2014). 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease. *Journal of the American College of Cardiology*, 60(24), e44–e164. <https://doi.org/10.1016/j.jacc.2012.07.013>
14. Gupta U, Kosey S, Pal R. Advancements in nanotechnology-based targeted drug delivery systems for glioblastoma chemotherapy: A comprehensive review. *Journal of Drug Delivery Science and Technology*. 2025 Sep 1;111:107181.
15. GBD 2019 Risk Factors Collaborators. (2020). Global burden of 87 risk factors in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. *The Lancet*, 396(10258), 1223–1249. [https://doi.org/10.1016/S0140-6736\(20\)30752-2](https://doi.org/10.1016/S0140-6736(20)30752-2)
16. Head, S. J., Milojevic, M., Daemen, J., Ahn, J. M., Boersma, E., Christiansen, E. H., ... & Kappetein, A. P. (2018). Mortality after coronary artery bypass grafting versus percutaneous coronary intervention with stenting for coronary artery disease: A pooled analysis of individual patient data. *The Lancet*, 391(10124), 939–948. [https://doi.org/10.1016/S0140-6736\(18\)30423-9](https://doi.org/10.1016/S0140-6736(18)30423-9)
17. Joshi, P., Islam, S., Pais, P., Reddy, S., Dorairaj, P., Kazmi, K., ... & Yusuf, S. (2007). Risk factors for early myocardial infarction in South Asians compared with individuals in other countries. *JAMA*, 297(3), 286–294. <https://doi.org/10.1001/jama.297.3.286>
18. Khan, A. R., Yang, X., Fu, M., Zhai, G. (2020). Recent progress of nanotechnology in cardiology. *European Journal of Pharmaceutical Sciences*, 147, 105291. <https://doi.org/10.1016/j.ejps.2020.105291>
19. Pachani, Sachin & Shah, Tapaskumar. (2021). Formulation of Paclitaxel-Encapsulated Polymeric Micelles For Targeted Breast Cancer Therapy. *Journal of Population Therapeutics and Clinical Pharmacology*. 28. 936-951. 10.53555/m318xt37.
20. Khera, A. V., Kathiresan, S., & Rader, D. J. (2016). Genetic risk, lifestyle, and coronary artery disease. *New England Journal of Medicine*, 375(24), 2349–2358. <https://doi.org/10.1056/NEJMoa1605086>
21. Lear, S. A., Hu, W., Rangarajan, S., Gasevic, D., Leong, D., Iqbal, R., ... & Yusuf, S. (2017). The effect of physical activity on mortality and cardiovascular disease in 130,000 people from 17 countries: The PURE study. *The Lancet*, 390(10113), 2643–2654. [https://doi.org/10.1016/S0140-6736\(17\)31634-3](https://doi.org/10.1016/S0140-6736(17)31634-3)
22. Vasanth S, Mishra R, Sahoo S, Parveen S, Khan Z, Mumtaz, Ruqaiya, Pal R. Advancing Mitochondrial Health in Huntington Disease (HD): Small Molecule Therapies and Neurodegeneration. *Current aging science*. 2025.
23. Libby, P. (2021). The changing landscape of atherosclerosis. *Nature*, 592(7855), 524–533. <https://doi.org/10.1038/s41586-021-03392-8>
24. Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F., Nauck, M., ... & LEADER Trial Investigators. (2016). Liraglutide and cardiovascular outcomes in type 2 diabetes. *New England Journal of Medicine*, 375(4), 311–322. <https://doi.org/10.1056/NEJMoa1603827>
25. Mills, K. T., Stefanescu, A., & He, J. (2020). The global epidemiology of hypertension. *Nature Reviews Nephrology*, 16(4), 223–237. <https://doi.org/10.1038/s41581-019-0244-2>
26. Mozaffarian, D. (2016). Dietary and policy priorities for cardiovascular disease, diabetes, and obesity. *Circulation*, 133(2), 187–225. <https://doi.org/10.1161/CIRCULATIONAHA.115.018585>
27. Pachani, Raj & Shah, Tapaskumar & Soni, Dhruv. (2021). Advances In Peptide-And Antibody-Targeted Nanocarriers For Cancer Therapy And Imaging. 28. 392-419. 10.53555/3sadm24.
28. Neumann, F. J., Sousa-Uva, M., Ahlsson, A., Alfonso, F., Banning, A. P., Benedetto, U., ... & Zembala, M. O. (2019). 2018 ESC/EACTS guidelines on myocardial revascularization. *European Heart Journal*, 40(2), 87–165. <https://doi.org/10.1093/eurheartj/ehy394>
29. Otto, C. M., Nishimura, R. A., Bonow, R. O., Carabello, B. A., Erwin, J. P., Gentile, F., ... & Yancy, C. W. (2021). 2020 ACC/AHA guideline for the management of patients with valvular heart disease. *Journal of the American College of Cardiology*, 77(4), e25–e197. <https://doi.org/10.1016/j.jacc.2020.11.018>

30. Shah, Tapaskumar. (2020). Advancing Formulation Science in Diabetes and Migraine: From Conventional Therapies to Precision Drug Delivery. *Journal of Cardiovascular Disease Research*. 11. 358-372.
31. Peters, S. A., Muntner, P., Woodward, M. (2019). Sex differences in the prevalence of, and trends in, cardiovascular risk factors, treatment, and control in the United States, 2001–2016. *Circulation*, 139(8), 1025–1035. <https://doi.org/10.1161/CIRCULATIONAHA.118.035550>
32. Preeti, Sambhakar, S., Malik, R., Bhatia, S., Harrasi, A. A., Saharan, R., ... & Rani, C. (2024). Lipid horizons: recent advances and future prospects in LBDDS for oral administration of antihypertensive agents. *International Journal of Hypertension*, 2024(1), 2430147.
33. Pal R, Pandey P, Chawra HS, Singh RP. Niosomal as potential vesicular drug nano-carriers for the treatment of tuberculosis (TB). *Nanoscience & Nanotechnology-Asia*. 2025 Feb;15(1):E22106812323829.
34. Preeti, Sambhakar, S., Malik, R., Bhatia, S., Al Harrasi, A., Rani, C., ... & Sehwat, R. (2023). Nanoemulsion: an emerging novel technology for improving the bioavailability of drugs. *Scientifica*, 2023(1), 6640103.
35. Rosengren, A., Smyth, A., Rangarajan, S., Ramasundarahettige, C., Bangdiwala, S. I., AlHabib, K. F., ... & Yusuf, S. (2019). Socioeconomic status and risk of cardiovascular disease in 20 low-income, middle-income, and high-income countries: The PURE study. *The Lancet Global Health*, 7(6), e748–e760. [https://doi.org/10.1016/S2214-109X\(19\)30045-2](https://doi.org/10.1016/S2214-109X(19)30045-2)
36. Mishra R, Pal R, Khan Z, Sahoo S, Chawra HS, Kumar D. Solid lipid nanoparticles (SLNPs): a state-of-the-art formulation strategy and their applications against tuberculosis (TB) and analgesic effects. *Nanoscience & Nanotechnology-Asia*. 2025 Jun;15(3):E22106812379362.
37. Roth, G. A., Mensah, G. A., Johnson, C. O., Addolorato, G., Ammirati, E., Baddour, L. M., ... & Fuster, V. (2020). Global burden of cardiovascular diseases and risk factors, 1990–2019: update from the GBD 2019 study. *Journal of the American College of Cardiology*, 76(25), 2982–3021. <https://doi.org/10.1016/j.jacc.2020.11.010>
38. Sahebkar, A., & Serban, M. C. (2015). Impact of polyphenols on cardiovascular disease. *Nutrients*, 7(9), 7657–7672.
39. Sarris, J. (2019). Integrative mental health and cardiovascular disease: The role of lifestyle, nutraceuticals, and mind–body practices. *BMC Complementary Medicine and Therapies*, 19(1), 7.
40. Koli M, Shah TM, Dutta P, Patel N, Patel AK, Ghosh B, Singh A, Pal R. Non-Ionic Surfactants (NIOs) in Niosome Drug Delivery: In-Depth Review of Clinical Trials, Patents in Tuberculosis (TB) and Oncology. *Current Nanomedicine*. 2025. doi:10.2174/0124681873413153251014082026
41. Steptoe, A., & Kivimäki, M. (2013). Stress and cardiovascular disease. *Nature Reviews Cardiology*, 9(6), 360–370. <https://doi.org/10.1038/nrcardio.2012.45>
42. Virani, S. S., Alonso, A., Aparicio, H. J., Benjamin, E. J., Bittencourt, M. S., Callaway, C. W., ... & American Heart Association Council. (2021). Heart disease and stroke statistics—2021 update: A report from the American Heart Association. *Circulation*, 143(8), e254–e743. <https://doi.org/10.1161/CIR.0000000000000950>
43. Whelton, P. K., Carey, R. M., Aronow, W. S., Casey Jr, D. E., Collins, K. J., Dennison Himmelfarb, C., ... & Wright Jr, J. T. (2018). 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APHA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults. *Hypertension*, 71(6), e13–e115. <https://doi.org/10.1161/HYP.0000000000000065>
44. World Health Organization (WHO). (2021). *Cardiovascular diseases (CVDs)*. Retrieved from [https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-\(cvds\)](https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds))
45. World Health Organization (WHO). (2021). *Global report on NCDs: Cardiovascular diseases*. Geneva: WHO Press.
46. Yusuf, S., Joseph, P., Rangarajan, S., Islam, S., Mente, A., Hystad, P., ... & O'Donnell, M. (2020). Modifiable risk factors, cardiovascular disease, and mortality in 155,722 individuals from 21 high-income, middle-income, and low-income countries (PURE): a prospective cohort study. *The Lancet*, 395(10226), 795–808. [https://doi.org/10.1016/S0140-6736\(19\)32008-2](https://doi.org/10.1016/S0140-6736(19)32008-2)
47. Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., ... & EMPA-REG OUTCOME Investigators. (2015). Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. *New England Journal of Medicine*, 373(22), 2117–2128. <https://doi.org/10.1056/NEJMoa1504720>